Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for ENLIVEN THERAPEUTICS INC Common Stock (ELVN).
- Disclosed ownership: 5.1%.
- Date of event: 30 Jun 2025.
BlackRock, Inc. - 30 Jun 2025 SCHEDULE 13G/A Report for ENLIVEN THERAPEUTICS INC Common Stock (ELVN)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- ELVN
- Shares outstanding
- 57,674,412 shares
- Disclosed Ownership
- 2,941,395 shares
- Ownership
- 5.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Jul 2025, 19:54:39 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 5.1% ownership in ENLIVEN THERAPEUTICS INC Common Stock (ELVN) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Jul 2025, 19:54.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.1% | 2,941,395 | 2,885,529 | 0 | Spencer Fleming | Managing Director |